Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689920 · ClinicalTrials.gov registry record · NA
Combining Mechanisms for Better Outcomes (COMBO)
A NA study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- NA
- Development phase
- 174
- Enrollment target
NCT03689920: Completed NA study, sponsored by Boston Scientific Corporation.
NCT03689920 is a NA study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 174 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03689920, a NA study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 174 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.
Primary Outcome
Percentage of subjects with 50% or greater reduction from Baseline Visit in average overall pain intensity at 3 months post-randomization with no increase in opioid medications
Interventions
- DEVICE Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2021-12-15 |
| Phase | NA |
What the finished NCT03689920 record still lists
NCT03689920 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System is the first listed.
NCT03689920 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03689920 about?
NCT03689920 is a clinical study titled "Combining Mechanisms for Better Outcomes (COMBO)". To evaluate the effectiveness of Spinal Cord Stimulation (SCS) with multiple modalities as compared to conventional SCS in patients with chronic pain when using the Boston Scientific Spectra WaveWriter SCS System.
What is the current status of trial NCT03689920?
This trial is currently completed. It is a NA study. The enrollment target is 174 participants. The study started on 2018-10-03. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT03689920?
The interventions under investigation include: Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System (DEVICE).
Who is sponsoring clinical trial NCT03689920?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03689920's enrollment target sits among peer trials
174 610th of 2000 higher than 1,390 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI